Evive Enters License Agreement with Acrotech Biopharma to Commercialize Ryzneuta™ in the United States

Evive Biotech has entered into a license agreement with Acrotech Biopharma, a New Jersey-based and wholly-owned subsidiary of Aurobindo Pharma USA Inc., to commercialize Ryzneuta™ i.e., Efbemalenograstim alfa in the US.

Related Keywords

China ,United States ,Yifan ,Zhejiang ,Chinese ,Ashish Anvekar ,Simon Li ,Acrotech Biopharma ,Yifan Pharmaceutical Co ,Aurobindo Pharma ,Aurobindo Pharma United States Inc ,Evive Enters License Agreement ,Commercialize Ryzneuta ,Yifan Pharmaceutical ,New Jersey Based ,Biologics License Application ,Marketing Authorization Application ,New Drug Application ,Aurobindo Pharma Limited ,Aurobindopharma ,Ine406a01037 ,Evivebiotech ,Us ,Licenseagreement ,Acrotechbiopharma ,Ryzneuta ,Efbemalenograstimalfa ,